Research and Clinical Trials

QUAD 0103
Brief Description  
With an estimated 33.2 million people in the world infected with the virus, human immunodeficiency virus (HIV) is a major medical problem. The purpose of this study is to see if the investigational compound of elvitegravir/emtricitabine/tenofovir/cobicistat (EVG/FTC/TDF/GS-9350) is safe and effective in reducing levels of HIV in the blood of subjects who are treatment-naïve (those who have not received any antiretroviral medication).
Who may be Eligible  
Inclusion criteria includes no history of prior antiretroviral therapy, viral load >5,000, normal ECG, glomerular filtration rate >70, adequate hematologic function, AST/ALT < 5 times upper limites of normal, adequate contraception for females and males of childbearing potential, age greater or equal to 18, and life expectancy greater than or equal to one year. Exclusion criteria includes a new AIDS defining condition diagnosed within 30 days of screening, anyone receiving/expected to receive Hep C drug treatment, cirrhosis, subjects with implanted defibrillators or pacemakers, a history of malignancy in the last 5 years (excluding Kaposi Sarcoma, basal cell carcinoma or noninvasive cutaneous squamous carcinoma), use of disallowed concomittant medications, and alcohol or substance abuse that would interfere with study compliance.
IRB Number  
Principal Investigator  
Johnson, Marc

For More Information, Contact  Jessica  A, Kearney-Bryan
Phone:  (704) 355-0244  Fax:  (704) 446-7641  
Address:3rd Floor Myers Park Clinic 1350 South King's Drive Charlotte, NC 28207